Semmelweis University

Department of Pharmacology and Pharmacotherapy

Pharmahungary Group


Péter Ferdinandy

The Cardiovascular and metabolic research group focuses on molecular medicine of ischemic heart disease and cardioprotection in the presence of cardiovascular comorbidities.

Prof. Dr. Ferdinandy is also founder and CEO of a group of R&D companies Pharmahungary Group. Pharmahungary offers preclinical and clinical R&D in cardiometabolic diseases, and develops cardioprotective therapies and biomarkers.


  • Cell culture, isolated organs, and animal models in cardiovascular and metabolic diseases

  • In vivo imaging

  • Transcriptomics

  • Bioinformatics (network analysis)

  • Extracellular vesicles

Interested in collaborating on

Techniques, signalling mechanisms and other topics related to lncRNA. Also open to participate in different H2020 applications.

Selected publications on ncRNA and cardiovascular disease

MicroRNA interactome analysis predicts post-transcriptional regulation of ADRB2 and PPP3R1 in the hypercholesterolemic myocardium
Ágg B, Baranyai T, Makkos A, Vető B, Faragó N, Zvara Á, Giricz Z, Veres DV, Csermely P, Arányi T, Puskás LG, Varga ZV, Ferdinandy PSci Rep. 2018, 8(1):10134.

Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart
Perrino C, Barabási AL, Condorelli G, Davidson SM, De Windt LDimmeler S, Engel FB, Hausenloy DJ, Hill JA, Van Laake LW, Lecour S, Leor J, Madonna R, Mayr M, Prunier F, Sluijter JPG, Schulz R, Thum T, Ytrehus K, Ferdinandy PCardiovasc Res. 113(7):725-736, 2017.

MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs
Varga ZV, Zvara A, Faragó N, Kocsis GF, Pipicz M, Gáspár R, Bencsik P, Görbe A, Csonka C, Puskás LG, Thum T, Csont T, Ferdinandy PAm J Physiol Heart Circ Physiol. 2014, 307(2):H216-27.